Approximately 100 CD133+ glioma cells were shown to be sufficient in a groundbreaking work to create xenografted tumors that accurately reflected the heterogeneity of the original tumor, while CD133- cells were efficiently depleted of their ability to cause tumors. The gene discussed is PROM1; the disease is central nervous system cancer.